|
Lantheus Medical Imaging has launched Ablavar (gadofosveset trisodium), an injectable MR angiography (MRA) imaging agent used to evaluate aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease.
The world medical ultrasound equipment, accessories, and maintenance services market is expected to reach $4.7 billion by 2012, according to market research firm Marketstrat.
Pharmalucence, a supplier of radiopharmaceutical products, has received approval from the FDA's Office of Generic Drugs for its abbreviated new drug application to manufacture and market its kit for the preparation of technetium Tc-99m Sestamibi injection.
Lantheus Medical Imaging has finalized an arrangement with the Australian Nuclear Science and Technology Organization to receive molybdenum-99 (Mo-99) produced from low-enriched uranium targets in its new Open Pool Australian Lightwater reactor.
Lantheus Medical Imaging has signed an agreement with NTP Radioisotopes, a subsidiary of the South African Nuclear Energy, to manufacture and supply Lantheus with an ongoing volume of molybdenum-99 (Mo-99).
Epix Pharmaceuticals has sold the U.S., Canadian and Australian rights for its blood pool MR angiography (MRA) agent, Vasovist, to Lantheus Medical Imaging for aggregate gross cash proceeds of $28 million. In addition, if Epix is unable to exchange all of its $100 million aggregate principal of 3 percent of convertible senior notes, it may be forced to file bankruptcy.
The utilization of contrast echocardiography in technically difficult cases improves endocardial visualization and impacts cardiac diagnosis, resource utilization and patient management, according to a study published online Feb. 11 in the Journal of the American College of Cardiology.
Arlington Medical Resources (AMR), which provides market data for the pharmaceutical and diagnostic imaging industries, has reported that Lantheus Medical Imaging’s Cardiolite had 15 percent more market share than GE Healthcare’s Myoview for September.
|
Lantheus Medical Imaging touted the benefits of its recently acquired MR angiography (MRA) agent, Ablavar (formerly marketed as Vasovist, gadofosveset trisodium), at the 2009 Radiological Society of North America in Chicago earlier this month.
Epix Pharmaceuticals reported Monday that it has decided to shut down due to a lack of capital and its inability to obtain additional financing or consummate a strategic transaction.
Lantheus Medical Imaging has been granted a supplemental new drug application from the FDA and a supplemental new drug submission from Health Canada to qualify the Australian Nuclear Science and Technology Organization as a valid supplier for low-enriched uranium-derived molybdenum-99 (Mo-99) to the United States and Canada.
Radiopharmaceutical provider PetNet Solutions, a wholly owned subsidiary of Siemens Medical Solutions, has executed a supply agreement with Lantheus Medical Imaging, a contrast agent and biomarker developer, to provide BMS747158 for PET imaging of cardiac perfusion as part of a Phase II and Phase III clinical trial.
DraxImage, a subsidiary of Jubilant Organosys of Noida, India, has received FDA approval for its abbreviated new drug application for its generic Sestamibi, a generic version of Lantheus Medical Imaging's Cardiolite.
Lantheus Medical Imaging has made a series of new hires to support its core business functions including regulatory affairs and quality operations.
There is potential diagnostic utility of SPECT myocardial perfusion imaging for ischemic left ventricular (LV) dysfunction in new-onset heart failure (HF), according to a non-randomized observational cohort published in the January/February issue of the Journal of Nuclear Cardiology.
Lantheus Medical Imaging has been awarded a three-year, sole-source supplier contract by Premier Purchasing Partners, the group purchasing unit of Premier, a U.S. healthcare group purchasing organization.
|
RSS 
The use of health IT to reduce rehospitalizations will be welcome but also disruptive, said Stephen Jencks, an independent consultant in healthcare safety during a Feb. 24 webinar on the potential use of health IT to mitigate rehospitalizations, sponsored by the Agency for Healthcare Research and Quality (AHRQ).
During the Health IT Standards Committee meeting on Feb. 24 in Washington, D.C., the Clinical Operations Workgroup sought to gather comments on proposed recommendations on implementation specifications for content exchange, vocabulary and code set standards for the Interim Final Rule of meaningful use.
In 2006, the Center for Devices and Radiological Health (CDRH), a branch of the FDA, began examining the number of medical device reports they received. Over the past two years, the number of submitted reports has increased, sparking a demand for the CDRH to make a move to electronic reporting.
A new hospital breaking ground usually isn’t breaking news. But the vision of patient care at one new facility, tentatively named Palomar Medical Center West (PMC West), is currently illegal under California state law.